{"schema_version":"secwatch.filing_event.v1","accession":"0001802768-24-000010","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.590817+00:00","generated_at":"2026-06-06T01:25:41.600357+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma Q4 Portfolio Receipts $736M (-31% YoY); FY23 $3,049M (+9%); FY24 guide $2.6-2.7B","bullets":["Portfolio Receipts Q4 $736M (down 31% YoY due to prior-year accelerated Biohaven payments); FY23 $3,049M (+9%).","FY24 guidance: Portfolio Receipts $2.6B-$2.7B, implying royalty receipts growth of 5-9% YoY.","Announced new transactions up to $4.0B in 2023; capital deployed $2.2B in 2023.","Repurchased ~10M shares for $305M in 2023 under $1B buyback program.","Positive clinical updates: aficamten Ph3 success, BMS to acquire Karuna, Novartis to acquire MorphoSys."],"urls":{"canonical":"https://secwatch.observer/filing/0001802768-24-000010","json":"https://secwatch.observer/filing/0001802768-24-000010.json","markdown":"https://secwatch.observer/filing/0001802768-24-000010.md","text":"https://secwatch.observer/filing/0001802768-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000010/0001802768-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000010/rprx-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:25:41.600357+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f879c005098bcc22f36500b850e290ff55424863","claim":"Royalty Pharma plc updated its the fourth quarter and full year of 2023 guidance (initiated).","evidence_excerpt":"On February 15, 2024, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000010/0001802768-24-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year of 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}